



26 June 2012

ASX Market Announcements
Australian Securities Exchange Limited
10th Floor, 20 Bond Street
SYDNEY NSW 2000

Australian Patent Granted for HLS5 Patent Family

BPH Energy Limited (ASX:**BPH**) investee company Molecular Discovery Systems Limited ("**MDS**") is pleased to announce that the Australian patent application has now been granted. The issued patent entitled 'Sumoylation control agent and uses thereof', patent number 2006302728, is valid until October 2026. The Australian patent is the fourth issued patent for MDS.

MDS has an extensive patent portfolio encapsulating the tumour suppressor gene HLS5, both as a potential cancer therapeutic target and also underpinning its involvement in a variety of other diseases. In recognition of its potential for detecting and treating cancer; outstanding organisations such as the NHMRC, the Cancer Council of WA, the National Breast Cancer Foundation, the Medical Research Foundation of Royal Perth Hospital and the Scott Kirkbride Melanoma Research Centre have awarded HLS5 research with high-priority funding. MDS will continue working with Professor Peter Klinken and his research group at the Western Australian Institute for Medical Research (WAIMR) with the aim of developing the HLS5 research to its full potential.

Yours sincerely,

David Breeze
Chairman

For Further Information

David Breeze
Chairman
tel: +61 (0) 8 9328 8366

david@bphenergy.com.au

BPH Energy Limited ACN 95 912 002
PO Box 317, North Perth, Western Australia 6906
14 View Street, North Perth, Western Australia 6006
admin@bphenergy.com.au www.bphenergy.com.au
T: +61 8 9328 8366 F: +61 8 9328 8733



Background:

MDS:

MDS is working with WAIMR to characterise and exploit the therapeutic potential of HLS5, for which it has an extensive patent portfolio. The HLS5 patent 'Tumour Suppressor Factor' has been issued in Australia and the United States. BPH Energy has a 20% residual interest in MDS after the spin-off of MDS in 2010. BPH Energy is working towards a listing of MDS on the Australian Securities Exchange.

WAIMR:

WAIMR is Western Australia's premier adult medical research institute and since its inception, WAIMR has made a number of internationally-significant research discoveries, including the identification of genes linked to asthma, leukaemia, breast, ovarian and prostate cancer, as well as those related to a number of nerve, muscle and mental health disorders.